Clinical Trial Update: A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. [Phase 1]

View source ↗

Summary

Phase 1 safety and dose-finding study of JNJ-26483327 in patients with advanced solid malignancies has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignant Neoplasms
• Solid Tumors

Drugs mentioned

• JNJ-26483327

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Protein Kinase Inhibitors, Antineoplastic Protocols | Phase 1 | Status: COMPLETED